<DOC>
	<DOCNO>NCT00408174</DOCNO>
	<brief_summary>To establish efficacy safety new tablet formulation dose regimen balsalazide disodium dose twice daily achieve clinical improvement subject mildly moderately active ulcerative colitis 6 week therapy .</brief_summary>
	<brief_title>Balsalazide Disodium vs. Mesalamine Mildly Moderately Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<mesh_term>Balsalazide</mesh_term>
	<criteria>mildly moderately active ulcerative colitis . disease extend least 20 cm rectum . baseline MMDAI score 610 , inclusive , great equal 2 MMDAI bleed component endoscopy/sigmoidoscopy component . take 4.8 grams/day Asacol , great equal 6.75 grams/day Colazal , 2.4 grams/day mesalamine equivalent daily dose use 5ASA product time 14 day precede initiation study medication . childbearing potential , negative serum pregnancy test . subject significant medical , include psychiatric , condition opinion investigator precludes participation study . subject history allergy intolerance aspirin , mesalamine , salicylate . subject 's UC worsen fail improve chronic ( i.e. , least 7 ) therapy great equal 6.6 g/day day balsalazide disodium within 30 day screen subject receive chronic ( i.e. , great 15 consecutive day ) immunosuppressive therapy ( e.g . azathioprine , 6 mercaptopurine ) corticosteroid within 30 day screen . Intermittent use oral rectal immunosuppressive therapy corticosteroid within 30 day screen permitted . Intravenous use corticosteroid within 30 day screen permitted . subject receive intrarectal aminosalicylates great 2 consecutive day within 7 day screen . subject prior bowel surgery , except appendectomy cholecystectomy . subject participate investigational drug device study within 30 day prior study . subject pregnant risk pregnancy , lactate ( female subject ) . subject show evidence current excessive alcohol consumption drug dependence . subject history human immunodeficiency virus ( HIV ) . Subjects history hepatitis B C eligible provide screen LFTs within normal limit . subject infectious , ischemic , immunologic disease GI involvement . subject twice upper limit normal ( ULN ) follow LFTs : alanine aminotransferase ( ALT/SGPT ) , aspartate aminotransferase ( AST/SGOT ) , alkaline phosphatase , total bilirubin ( except isolate elevation unconjugated bilirubin ) . subject uncontrolled , clinically significant renal disease manifest 1.5 Ã— ULN serum creatinine . subject calculated creatinine clearance level less equal 60 mL/min . subject unstable cardiovascular , coagulopathy pulmonary disease characterize worsen disease condition require change treatment medical care within one ( 1 ) month randomization . subject active malignancy within last 5 year , except basal cell carcinoma skin , female , situ cervical carcinoma surgically excise . subject condition circumstance would , opinion investigator , prevent completion study interfere analysis study result , include history noncompliance treatment visit . subject sclerosing cholangitis . subject positive stool culture ovum parasite ( O &amp; P ) C. difficile . subject treat infliximab , cyclosporine , natalizumab , methotrexate ulcerative colitis within last 30 day prior screen . regular use NSAIDS except cardioprotective ASA ( i.e. , less equal 162 mg ASA per day ) . subject receive celldepleting therapy Adacolumn . subject require antidiarrheal therapy screening . subject clinical radiographic finding suggestive serious UC complication toxic megacolon colonic perforation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>IBD</keyword>
	<keyword>UC</keyword>
	<keyword>Ulcerative Colitis</keyword>
	<keyword>Inflammatory Bowel Disease</keyword>
</DOC>